Notícias ARS Pharmaceuticals Inc - SPRY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (SPRY) Notícias

ARS Pharmaceuticals Inc (SPRY)

13,38

-0,17

(-1,25%)

No fechamento: 21 Novembro 6:00PM

Atrasado por 15 minutos

13,38

-0,015

( -0,11% )

Após o horário de negociação: 6:03PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

ARS Pharmaceuticals

Spring Valley Acquisitio...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições